Mike Yong
2024-12-27
$Recursion Pharmaceuticals, Inc.(RXRX)$  


Recent upward momentum in Recursion's stock price underscores growing confidence in its cutting-edge approach to modern drug discovery. It is poised to reshape how new therapies are developed, accelerating timelines and expanding the horizon of treatable diseases.


Along with the tailwinds from AI enthusiasm, the recent stock price increase highlights a broader recognition of AI-driven drug discovery's promise.


With new therapies advancing through the pipeline and additional data readouts on the horizon, Recursion sits in the cusp of potentially significant value-creation milestones. [Eye]  

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • Tigerous
    2024-12-27
    Tigerous
    It’s been down for so long…
    • Mike Yong
      And it will be up soon. Next generation of AI applications are not just about LLM or LVM anymore. It’s about using AI to potentially serve the people for the betterment of society.
Leave a comment
2
1